SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dynavax Technologies Corp. & Encourages In...
November 21 2016 - 7:39PM
Business Wire
Lundin Law PC, a shareholder rights firm, announces the filing
of a class action lawsuit against Dynavax Technologies Corporation
(“Dynavax” or the “Company”) (Nasdaq: DVAX) concerning possible
violations of federal securities laws between March 10, 2014 and
November 11, 2016 inclusive (the “Class Period”). Investors who
purchased or otherwise acquired shares during the Class Period
should contact the firm in advance of the January 17, 2017 lead
plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esquire, of Lundin Law PC, at
888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
According to the Complaint, Dynavax made false and/or misleading
statements and/or failed to disclose: that the phase 3 HBV-23 trial
for the Company’s lead vaccine product HEPLISAV-B was not designed
in accordance with the U.S. Food and Drug Administration’s concerns
and issues; that the Company failed to provide sufficient
information to the FDA in its Revised Biologics License Application
for the drug; that Dynavax’s resources will not be sufficient for
the Company to advance the HEPLISAV-B program on its own; and that
as a result of the above, the Company’s financial statements and
statements about its business, operations, and prospects were false
and misleading and/or lacked a reasonable basis.
On November 14, 2016, Dynavax announced that it received a
Complete Response Letter from the U.S. Food and Drug Administration
requesting additional information on the Company’s HEPLISAV-B
product in connection with its Biologics License Application.
Lundin Law PC was founded by Brian Lundin, a securities
litigator based in Los Angeles dedicated to upholding the rights of
shareholder.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161121006268/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024